The evolving landscape of pulmonary arterial hypertension clinical trials

PHA Canada
Nov 26, 2022
1 min read

Updated: Nov 7, 2024

In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance requires longer studies with more participants. Given that PAH is a rare disease, finding large numbers of participants is a problem. Innovative trial designs offer new options while still providing good data.

Read the original journal article

Recent Posts

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

Smoking delays PAH diagnosis, but not CTEPH

Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension

Comments